Acromegaly treatment linked to sleep apnea improvement

  • Wolters TLC & al.
  • J Clin Endocrinol Metab
  • 15/10/2019

  • Brian Richardson, PhD
  • Clinical Essentials
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Treatment for acromegaly is associated with decreases in the prevalence and severity of obstructive sleep apnea syndrome (OSAS).

Why this matters

  • Sleep apnea shows increased incidence in patients with acromegaly as a result of craniofacial abnormalities and tissue growth in the upper respiratory tract.

Key results

  • Treatment for acromegaly was associated with improvements in the Respiratory Disturbance Index (RDI; P=.001), Oxygen Desaturation Index (ODI; P=.001), lowest oxygen saturation (LSaO2; P=.007), and Epworth Sleepiness Scale (ESS; P<.001>
  • 30% of analyzed patients with OSAS at baseline were cured of OSAS at 1 year.
  • 68.8% of analyzed patients with OSAS at baseline were cured of OSAS at 2.5 years.
  • Levels of IGF-1 correlated with OSAS severity (P=.049), and decreases in IGF-1 correlated with improvements in RDI (P<.001 odi lsao>2 (P=.003), and ESS (P<.001>

Study design

  • 27 patients with treatment-naive acromegaly who received polysomnography; 74.1% diagnosed with OSAS, were included.
  • Funding: Ipsen Pharmaceuticals.

Limitations

  • Small patient sample size.